AstraZeneca PLC (AZN)
| Market Cap | 280.97B +27.7% |
| Revenue (ttm) | 60.44B +9.9% |
| Net Income | 10.39B +33.7% |
| EPS | 6.64 +33.6% |
| Shares Out | 1.55B |
| PE Ratio | 27.04 |
| Forward PE | 17.06 |
| Dividend | $3.20 (1.76%) |
| Ex-Dividend Date | Feb 20, 2026 |
| Volume | 1,123,847 |
| Open | 181.36 |
| Previous Close | 178.96 |
| Day's Range | 180.39 - 183.27 |
| 52-Week Range | 134.90 - 212.71 |
| Beta | 0.21 |
| Analysts | Strong Buy |
| Price Target | 224.49 (+22.95%) |
| Earnings Date | Jul 28, 2026 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for AZN stock is "Strong Buy." The 12-month stock price target is $224.49, which is an increase of 22.95% from the latest price.
News
BioInvent's BI-1206 Triplet Achieves 83% Response Rate in Refractory NHL with Improved Safety vs. SOC (EHA 2026)
BioInvent will host an in-person KOL lunch briefing (11:45 a.m. - 2:00 p.m.
AstraZeneca gets CDSCO approval to sell Enhertu in India for first-line HER2-positive breast cancer treatment
AstraZeneca Pharma India Limited received permission from the Central Drugs Standard Control Organisation on June 10, 2026, to import for sale and distribution of Trastuzumab deruxtecan 100 mg/5mL via...
Morning Mail: One Nation’s ‘sloppy’ finances, Trump signals new Iran strikes, who will win the World Cup?
Want to get this in your inbox every weekday? Sign up for the Morning Mail here , and finish your day with our Afternoon Update newsletter Morning everyone. Our top story today focuses on One Nation –...
Breast cancer and endometriosis drug Zoladex is being pulled from Australia. How will women be affected?
The vital medicine, made by AstraZeneca, will not be available from November, possibly leaving thousands of women without treatment Get our breaking news email , free app or daily news podcast Thousan...
GSK steps up cancer fight as new boss Luke Miels signals a change of direction: ALEX BRUMMER
The choice of Aussie Luke Miels as GSK's chief exec, previously a lieutenant of Pascal Soriot at AstraZeneca, signalled a change of direction.
AstraZeneca's obesity drug shows promise as analysts see upside beyond consensus
AstraZeneca is emerging as a potential new contender in the booming obesity treatment market after its experimental weight-loss pill delivered encouraging mid-stage trial results, prompting investors ...
AstraZeneca (AZN) Advances Elecoglipron to Phase 3 Trials After Positive Results
AstraZeneca (AZN) Advances Elecoglipron to Phase 3 Trials After Positive Results
AstraZeneca Transcript: Investor update
Phase IIb data for elecoglipron show robust, dose-dependent weight loss and glycemic control in obesity and type 2 diabetes, with a safety profile consistent with GLP-1 agonists. An ambitious phase III program will target obesity, diabetes, heart failure, and CKD, leveraging combination therapies and global reach.
AstraZeneca Slides: Investor update
AstraZeneca has posted slides in relation to its latest quarterly earnings report, which was published on June 8, 2026.
AstraZeneca (AZN) Reports Promising Phase IIb Results for Elecoglipron
AstraZeneca (AZN) Reports Promising Phase IIb Results for Elecoglipron
AstraZeneca advancing elecoglipron into Phase 3 program in obesity, T2D
Positive results from the VISTA and SOLSTICE Phase IIb trials of elecoglipron, an oral small molecule GLP-1 receptor agonist, “unlock the next chapter in AstraZeneca’s (AZN) ambition to develop therap...
AstraZeneca obesity pill helps patients lose 10.5% of body weight in trial
AstraZeneca said on Monday that patients lost 10.5% of their body weight after 26 weeks in a mid-stage trial of its experimental obesity pill, as the drugmaker seeks to challenge Novo Nordisk and Eli...
Top 10 London Stock Exchange Stocks to Consider Buying in 2026 for UK Exposure
The London Stock Exchange sees renewed momentum in 2026, with the FTSE 100 surpassing 10,000 points. Key stocks like AstraZeneca and Shell offer growth and resilience amid global economic shifts.
AstraZeneca CEO: AI helps us make smarter choices when developing drugs
AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk quarterly results, drug development, AI integration, and more.
AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer
AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk quarterly results, drug development, AI integration, and more.
AstraZeneca CEO says AI is reshaping drug development — and helping boost the odds of success
AstraZeneca CEO Pascal Soriot said artificial intelligence is helping the company develop medicines faster, identify promising drug targets, and improve the odds of success in costly clinical trials. ...
NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, June 5, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NY...
AstraZeneca PLC (AZN) Shares Surge 3.1% -- What GF Score of 83 Tells Investors
AstraZeneca PLC (AZN) Shares Surge 3.1% -- What GF Score of 83 Tells Investors
AstraZeneca (AZN) Engages with FDA Leadership on Rare Disease Initiatives
AstraZeneca (AZN) Engages with FDA Leadership on Rare Disease Initiatives
FTSE 100 drops amid China banking concerns and falling oil prices
The UK's benchmark FTSE 100 index fell to its lowest level in more than two weeks on Thursday, weighed down by sharp declines in Asia-focused lenders and miners after reports of tighter offshore banki...
AstraZeneca CEO: AI is affecting every part of our company
AstraZeneca CEO Pascal Soriot joins CNBC’s Angelica Peebles to discuss the most promising drugs in AstraZeneca’s pipeline. He says the future is about innovating into new indications with the drugs an...
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment For Ampligen In Pancreatic Cancer; Stock Down
(RTTNews) - AIM ImmunoTech Inc. (AIM), an immune pharma company, announced the final enrolment of subjects in the Phase 2 clinical trial dubbed DURIPANC, evaluating AIM's drug Ampligen (rintatolimod) ...
AstraZeneca (AZN) Benefits from New FDA Guidance on Gene Therapy Development
AstraZeneca (AZN) Benefits from New FDA Guidance on Gene Therapy Development
AstraZeneca's Camizestrant Shows Strong Results in Phase III Trial (AZN)
AstraZeneca's Camizestrant Shows Strong Results in Phase III Trial (AZN)
AstraZeneca (AZN) Reports Promising Phase III Trial Results for Camizestrant
AstraZeneca (AZN) Reports Promising Phase III Trial Results for Camizestrant